Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival.
Hematopoietic cell transplantation (HCT)
hematopoietic cell transplantation comorbidity index (HCT-CI)
rehabilitation
rehabilitation facility
skilled nursing facility (SNF)
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
23
06
2020
revised:
30
10
2020
accepted:
17
11
2020
entrez:
10
4
2021
pubmed:
11
4
2021
medline:
3
7
2021
Statut:
ppublish
Résumé
Many hematopoietic cell transplantation (HCT) recipients require rehabilitation due to deconditioning following intensive conditioning regimens and immune reconstitution. HCT recipients are preferentially discharged to home to avoid the risk of exposure to healthcare-associated infection in a rehabilitation facility (RF), with a caregiver who has been provided specific education about the complexity of post-HCT care. This study was conducted to determine the incidence of discharge to an RF following HCT, identify pre-HCT and peri-HCT risk factors for discharge to an RF, and estimate the effect of discharge disposition on overall survival (OS). This retrospective, matched 1:4 case-control study included 56 cases over a 10-year period from a single institution. Controls were matched by transplantation type (autologous versus allogeneic) and date of transplantation. The incidence of discharge to an RF was 2.2%. Controlling for disease, increasing age (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.04 to 1.15; P < .001), female sex (OR, 3.11; 95% CI, 1.32 to 7.32; P = .01), high-risk HCT Comorbidity Index (HCT-CI) score (≥3) (OR, 3.44; 95% CI, 1.39 to 8.52; P = .008), decreasing pre-HCT serum albumin (OR, 2.60; 95% CI, 1.07 to 6.38; P = .037), and development of acute kidney injury during HCT (OR, 4.10; 95% CI, 1.36 to 12.40; P = .012) were associated with discharge to an RF. Discharge to an RF was associated with worse OS and higher nonrelapse mortality (NRM) compared with discharge to home (1-year OS, 70.5% [95% CI, 55.8% to 81.1%] versus 88.8% [95% CI, 83.6% to 92.4%], P < .001; 100-day NRM: 9.5% [95% CI, 3.5% to 19.2%] versus 1.8% [95% CI, 0.6% to 4.3%]; P = .03). Discharge to an RF following HCT is a rare event but associated with poor OS. Modifiable risk factors for discharge to an RF, including serum albumin as a measure of nutrition and reversible HCT-CI components, should be prospectively studied to determine the effect of mitigation on discharge disposition and survival.
Identifiants
pubmed: 33836883
pii: S2666-6367(20)30041-5
doi: 10.1016/j.jtct.2020.11.015
pmc: PMC8036236
mid: NIHMS1673919
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
337.e1-337.e7Subventions
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA165998
Pays : United States
Informations de copyright
Copyright © 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
Biol Blood Marrow Transplant. 2020 Jan;26(1):189-196
pubmed: 31493541
Lancet Oncol. 2012 Oct;13(10):e437-44
pubmed: 23026829
J Am Geriatr Soc. 2018 May;66(5):930-936
pubmed: 29500814
Cancer J. 2017 Jul/Aug;23(4):201-205
pubmed: 28731941
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Pediatr Transplant. 2017 Sep;21(6):
pubmed: 28670844
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
Clin Infect Dis. 2003 Apr 1;36(7):870-6
pubmed: 12652388
Bone Marrow Transplant. 2015 Oct;50(10):1379-81
pubmed: 26121107
J Clin Oncol. 2016 Jul 10;34(20):2366-71
pubmed: 27185838
Bone Marrow Transplant. 2020 Jan;55(1):157-164
pubmed: 31471572
Arthritis Care Res (Hoboken). 2017 Nov;69(11):1668-1675
pubmed: 28118530
J Gastrointest Surg. 2015 Feb;19(2):207-16
pubmed: 25373704
Transplant Proc. 2013 Nov;45(9):3371-4
pubmed: 24182818
Pediatr Blood Cancer. 2018 Feb;65(2):
pubmed: 29080380
Am J Phys Med Rehabil. 2018 Jun;97(6):440-449
pubmed: 29360647
Bone Marrow Transplant. 2018 Nov;53(11):1418-1427
pubmed: 29445123
PLoS One. 2015 Dec 18;10(12):e0145445
pubmed: 26683031
Biol Blood Marrow Transplant. 2015 Oct;21(10):1707-13
pubmed: 26172477
Nutr Cancer. 2017 Nov-Dec;69(8):1205-1210
pubmed: 28937794